{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-26-000036","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.910658+00:00","generated_at":"2026-05-14T23:43:35.816883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance","bullets":["GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.","Revenue $200.4M (+2% YoY); Cancer Care +4%, Prenatal -15%, Mental Health +24%.","Test volumes 385k flat YoY; Cancer Care +13%, Prenatal -12%, Mental Health +7%.","Launched Precise MRD (ultrasensitive assay) and received FDA approval for MyChoice CDx as Zejula companion diagnostic.","Reiterated FY 2026 guidance: revenue $860-880M, adjusted EBITDA $37-49M, adj. gross margin 68-69%."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-26-000036","json":"https://secwatch.observer/filing/0000899923-26-000036.json","markdown":"https://secwatch.observer/filing/0000899923-26-000036.md","text":"https://secwatch.observer/filing/0000899923-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/0000899923-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/mygn-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:43:35.816883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcc10ccc87d8dff809551a13c263884376be4083","claim":"MYRIAD GENETICS INC reported first quarter ended March 31, 2026 results: revenue 200.4 million, net income net loss of $34.1 million, EPS loss per share was $0.09 per share. Guidance reaffirmed.","evidence_excerpt":"First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/0000899923-26-000036-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"200.4 million"},{"label":"Net income","value":"net loss of $34.1 million"},{"label":"EPS","value":"loss per share was $0.09 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}